Analysts Set Syros Pharmaceuticals (SYRS) Target Price at $22.43

Share on StockTwits

Syros Pharmaceuticals (NASDAQ:SYRS) has been assigned a consensus recommendation of “Hold” from the eleven research firms that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $22.43.

Several research firms recently commented on SYRS. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 16th. BidaskClub lowered shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 24th. HC Wainwright reaffirmed a “hold” rating and set a $10.00 target price on shares of Syros Pharmaceuticals in a report on Wednesday, March 14th. Cann reaffirmed a “buy” rating and set a $28.00 target price on shares of Syros Pharmaceuticals in a report on Thursday, May 10th. Finally, ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 6th.

Syros Pharmaceuticals opened at $10.97 on Monday, Marketbeat Ratings reports. Syros Pharmaceuticals has a 52 week low of $6.30 and a 52 week high of $24.38. The firm has a market cap of $338.16 million, a P/E ratio of -5.15 and a beta of -2.57.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, May 10th. The company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.14). The company had revenue of $0.37 million for the quarter, compared to the consensus estimate of $3.41 million. research analysts forecast that Syros Pharmaceuticals will post -2.2 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Redmile Group LLC boosted its position in Syros Pharmaceuticals by 159.3% during the 1st quarter. Redmile Group LLC now owns 1,652,240 shares of the company’s stock valued at $21,446,000 after buying an additional 1,015,008 shares during the period. BlackRock Inc. boosted its position in Syros Pharmaceuticals by 61.7% during the 1st quarter. BlackRock Inc. now owns 929,537 shares of the company’s stock valued at $12,066,000 after buying an additional 354,591 shares during the period. JPMorgan Chase & Co. boosted its position in Syros Pharmaceuticals by 13.9% during the 1st quarter. JPMorgan Chase & Co. now owns 374,513 shares of the company’s stock valued at $4,861,000 after buying an additional 45,715 shares during the period. Northern Trust Corp boosted its position in Syros Pharmaceuticals by 35.0% during the 1st quarter. Northern Trust Corp now owns 181,090 shares of the company’s stock valued at $2,351,000 after buying an additional 46,927 shares during the period. Finally, Millennium Management LLC purchased a new stake in Syros Pharmaceuticals during the 1st quarter valued at $2,126,000. 56.84% of the stock is owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.